Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407135 | 0.89 | TRPV1 (0.52) | BPTFTRPV1MEN1CYP1A2KMT2A | |
| SCHEMBL2743006 | 0.81 | TRPV1 (0.46) | BPTFTRPV1CHRNB2CHRNA4HTR2C | |
| SCHEMBL1752994 | 0.77 | TRPV1 (0.44) | TRPV1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3542274 | 0.76 | TRPV1 (0.58) | TRPV1ALDH1A1MEN1KMT2A | |
| SCHEMBL5466686 | 0.74 | CHRNB2 (0.51) | CHRNB2CHRNA4ADRB1CHRM2CHRM4 | |
| SCHEMBL195203 | 0.73 | BPTF (0.51) | BPTFCHRNB2CHRNA4ADRB1CHRM2 | |
| SCHEMBL30282824 | 0.73 | BPTF (0.51) | BPTFCHRNB2CHRNA4ADRB1CHRM2 | |
| SCHEMBL1828990 | 0.73 | PDE10A (0.50) | BPTFCHRNB2CHRNA4ADRB1CHRM2 | |
| SCHEMBL1752949 | 0.72 | NPY5R (0.49) | ADRB1ALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL23432511 | 0.71 | TRPV1 (0.38) | TRPV1ALDH1A1CYP1A2CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| WO-2004011441-A1 | PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200472-A1 | Therapeutic agents useful for treating pain | HRH2, OPRL1, TRPV1 | BPTF 2373/4885TRPV1 3/4885CHRNB2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.